Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic

Glioblastoma multiforme (GBM) is the most common and aggressive malignant brain tumour. Patients afflicted with this disease unfortunately have a very poor prognosis, and fewer than 5% of patients survive for 5 years from the time of diagnosis. Therefore, improved therapies to treat this disease are...

Descripción completa

Detalles Bibliográficos
Autores principales: Shabason, Jacob E, Tofilon, Philip J, Camphausen, Kevin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2011
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112261/
https://www.ncbi.nlm.nih.gov/pubmed/21362133
http://dx.doi.org/10.1111/j.1582-4934.2011.01296.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112261/
https://www.ncbi.nlm.nih.gov/pubmed/21362133
http://dx.doi.org/10.1111/j.1582-4934.2011.01296.x

Ejemplares similares